Leach C A, Brown T H, Ife R J, Keeling D J, Laing S M, Parsons M E, Price C A, Wiggall K J
SmithKline Beecham Pharmaceuticals R&D, Welwyn, Herts, England.
J Med Chem. 1992 May 15;35(10):1845-52. doi: 10.1021/jm00088a021.
Further work on compounds 1 has identified the 4-position as a site where substantial modifications are tolerated, leading to analogues which are more potent and less toxic than those described previously. The best compound in the series is 13a (SK&F 96356), which is a potent inhibitor of gastric acid secretion in both the pentagastrin-stimulated rat and the histamine-stimulated dog. This compound shows reversible, K(+)-competitive binding to the enzyme. Because of its fluorescent properties, it is also proving useful in vitro as a probe of the structure and function of the (H+/K+)-ATPase.